Cargando…

Assuring Consistent Performance of an Insulin-Like Growth Factor 1 MALDImmunoassay by Monitoring Measurement Quality Indicators

[Image: see text] Analytical methods based on mass spectrometry (MS) have been successfully applied in biomarker discovery studies, while the role of MS in translating biomarker candidates to clinical diagnostics is less pronounced. MALDImmunoassays—methods that combine immunoaffinity enrichment wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Klont, Frank, ten Hacken, Nick H. T., Horvatovich, Péter, Bakker, Stephan J. L., Bischoff, Rainer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2017
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5463271/
https://www.ncbi.nlm.nih.gov/pubmed/28467045
http://dx.doi.org/10.1021/acs.analchem.7b01125
_version_ 1783242671732555776
author Klont, Frank
ten Hacken, Nick H. T.
Horvatovich, Péter
Bakker, Stephan J. L.
Bischoff, Rainer
author_facet Klont, Frank
ten Hacken, Nick H. T.
Horvatovich, Péter
Bakker, Stephan J. L.
Bischoff, Rainer
author_sort Klont, Frank
collection PubMed
description [Image: see text] Analytical methods based on mass spectrometry (MS) have been successfully applied in biomarker discovery studies, while the role of MS in translating biomarker candidates to clinical diagnostics is less pronounced. MALDImmunoassays—methods that combine immunoaffinity enrichment with matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometric detection—are attractive analytical approaches for large-scale sample analysis by virtue of their ease of operation and high-throughput capabilities. Despite this fact, MALDImmunoassays are not widely used in clinical diagnostics, which is mainly due to the limited availability of internal standards that can adequately correct for variability in sample preparation and the MALDI process itself. Here we present a novel MALDImmunoassay for quantification of insulin-like growth factor 1 (IGF1) in human plasma. Reliable IGF1 quantification in the range of 10–1000 ng/mL was achieved by employing (15)N-IGF1 as internal standard, which proved to be an essential feature of the IGF1 MALDImmunoassay. The method was validated according to U.S. Food and Drug Administration (FDA) guidelines, which included demonstrating the effectiveness of IGF1/IGF binding protein (IGF1/IGFBP) complex dissociation using sodium dodecyl sulfate (SDS). Furthermore, the MALDImmunoassay compared well with the IDS-iSYS IGF1 immunoassay with high correlation (R(2) = 0.99), although substantially lower levels were reported by the MALDImmunoassay. The method was tested on >1000 samples from a cohort of renal transplant recipients to assess its performance in a clinical setting. On the basis of this study, we identified readouts to monitor the quality of the measurements. Our work shows that MALDI-TOF mass spectrometry is suitable for quantitative biomarker analysis provided that an appropriate internal standard is used and that readouts are monitored to assess the quality of the measurements.
format Online
Article
Text
id pubmed-5463271
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-54632712017-06-12 Assuring Consistent Performance of an Insulin-Like Growth Factor 1 MALDImmunoassay by Monitoring Measurement Quality Indicators Klont, Frank ten Hacken, Nick H. T. Horvatovich, Péter Bakker, Stephan J. L. Bischoff, Rainer Anal Chem [Image: see text] Analytical methods based on mass spectrometry (MS) have been successfully applied in biomarker discovery studies, while the role of MS in translating biomarker candidates to clinical diagnostics is less pronounced. MALDImmunoassays—methods that combine immunoaffinity enrichment with matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometric detection—are attractive analytical approaches for large-scale sample analysis by virtue of their ease of operation and high-throughput capabilities. Despite this fact, MALDImmunoassays are not widely used in clinical diagnostics, which is mainly due to the limited availability of internal standards that can adequately correct for variability in sample preparation and the MALDI process itself. Here we present a novel MALDImmunoassay for quantification of insulin-like growth factor 1 (IGF1) in human plasma. Reliable IGF1 quantification in the range of 10–1000 ng/mL was achieved by employing (15)N-IGF1 as internal standard, which proved to be an essential feature of the IGF1 MALDImmunoassay. The method was validated according to U.S. Food and Drug Administration (FDA) guidelines, which included demonstrating the effectiveness of IGF1/IGF binding protein (IGF1/IGFBP) complex dissociation using sodium dodecyl sulfate (SDS). Furthermore, the MALDImmunoassay compared well with the IDS-iSYS IGF1 immunoassay with high correlation (R(2) = 0.99), although substantially lower levels were reported by the MALDImmunoassay. The method was tested on >1000 samples from a cohort of renal transplant recipients to assess its performance in a clinical setting. On the basis of this study, we identified readouts to monitor the quality of the measurements. Our work shows that MALDI-TOF mass spectrometry is suitable for quantitative biomarker analysis provided that an appropriate internal standard is used and that readouts are monitored to assess the quality of the measurements. American Chemical Society 2017-05-03 2017-06-06 /pmc/articles/PMC5463271/ /pubmed/28467045 http://dx.doi.org/10.1021/acs.analchem.7b01125 Text en Copyright © 2017 American Chemical Society This is an open access article published under a Creative Commons Non-Commercial No Derivative Works (CC-BY-NC-ND) Attribution License (http://pubs.acs.org/page/policy/authorchoice_ccbyncnd_termsofuse.html) , which permits copying and redistribution of the article, and creation of adaptations, all for non-commercial purposes.
spellingShingle Klont, Frank
ten Hacken, Nick H. T.
Horvatovich, Péter
Bakker, Stephan J. L.
Bischoff, Rainer
Assuring Consistent Performance of an Insulin-Like Growth Factor 1 MALDImmunoassay by Monitoring Measurement Quality Indicators
title Assuring Consistent Performance of an Insulin-Like Growth Factor 1 MALDImmunoassay by Monitoring Measurement Quality Indicators
title_full Assuring Consistent Performance of an Insulin-Like Growth Factor 1 MALDImmunoassay by Monitoring Measurement Quality Indicators
title_fullStr Assuring Consistent Performance of an Insulin-Like Growth Factor 1 MALDImmunoassay by Monitoring Measurement Quality Indicators
title_full_unstemmed Assuring Consistent Performance of an Insulin-Like Growth Factor 1 MALDImmunoassay by Monitoring Measurement Quality Indicators
title_short Assuring Consistent Performance of an Insulin-Like Growth Factor 1 MALDImmunoassay by Monitoring Measurement Quality Indicators
title_sort assuring consistent performance of an insulin-like growth factor 1 maldimmunoassay by monitoring measurement quality indicators
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5463271/
https://www.ncbi.nlm.nih.gov/pubmed/28467045
http://dx.doi.org/10.1021/acs.analchem.7b01125
work_keys_str_mv AT klontfrank assuringconsistentperformanceofaninsulinlikegrowthfactor1maldimmunoassaybymonitoringmeasurementqualityindicators
AT tenhackennickht assuringconsistentperformanceofaninsulinlikegrowthfactor1maldimmunoassaybymonitoringmeasurementqualityindicators
AT horvatovichpeter assuringconsistentperformanceofaninsulinlikegrowthfactor1maldimmunoassaybymonitoringmeasurementqualityindicators
AT bakkerstephanjl assuringconsistentperformanceofaninsulinlikegrowthfactor1maldimmunoassaybymonitoringmeasurementqualityindicators
AT bischoffrainer assuringconsistentperformanceofaninsulinlikegrowthfactor1maldimmunoassaybymonitoringmeasurementqualityindicators